Business Description

Bright Minds Biosciences Inc
NAICS : 325412
SIC : 3741
Compare
Compare
Traded in other countries / regions
DRUG.CanadaDRUG.USA IPO Date
2021-02-08Description
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 88.73 | |||||
Equity-to-Asset | 0.9 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 33.51 | |||||
9-Day RSI | 43.33 | |||||
14-Day RSI | 46.91 | |||||
6-1 Month Momentum % | -41.78 | |||||
12-1 Month Momentum % | -35.61 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 9.83 | |||||
Quick Ratio | 9.83 | |||||
Cash Ratio | 9.61 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History |
---|
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -100.75 | |||||
ROA % | -92.28 | |||||
ROIC % | -8516.44 | |||||
ROC (Joel Greenblatt) % | -8136.36 | |||||
ROCE % | -98.82 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.58 | |||||
Price-to-Tangible-Book | 1.6 | |||||
EV-to-EBIT | -0.47 | |||||
EV-to-EBITDA | -0.47 | |||||
EV-to-FCF | -0.5 | |||||
Price-to-Net-Current-Asset-Value | 1.6 | |||||
Price-to-Net-Cash | 1.63 | |||||
Earnings Yield (Greenblatt) % | -212.77 |
Balance Sheet Breakdown
Cashflow Statement Breakdown
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Bright Minds Biosciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil C$) | |||
EPS (TTM) (C$) | -0.66 | ||
Beta | 0 | ||
Volatility % | 122.59 | ||
14-Day RSI | 46.91 | ||
14-Day ATR (C$) | 0.06367 | ||
20-Day SMA (C$) | 0.77 | ||
12-1 Month Momentum % | -35.61 | ||
52-Week Range (C$) | 0.54 - 6.07 | ||
Shares Outstanding (Mil) | 18.86 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Bright Minds Biosciences Inc Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |
Bright Minds Biosciences Inc Stock Events
Event | Date | Price(C$) | ||
---|---|---|---|---|
No Event Data |
Bright Minds Biosciences Inc Frequently Asked Questions
What is Bright Minds Biosciences Inc(XCNQ:DRUG)'s stock price today?
The current price of XCNQ:DRUG is C$0.75. The 52 week high of XCNQ:DRUG is C$6.07 and 52 week low is C$0.54.
When is next earnings date of Bright Minds Biosciences Inc(XCNQ:DRUG)?
The next earnings date of Bright Minds Biosciences Inc(XCNQ:DRUG) is 2023-08-30 Est..
Does Bright Minds Biosciences Inc(XCNQ:DRUG) pay dividends? If so, how much?
Bright Minds Biosciences Inc(XCNQ:DRUG) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |